Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz

Q: What Schools Are Affiliated With Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz is affiliated with the following schools: University of Palermo, United States Military Academy, University of North Carolina at Chapel Hill, Thomas Jefferson University, Kyoto University

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz's AcademicInfluence.com Rankings

Biology

#12757

World Rank

#16255

Historical Rank

Virology

#309

World Rank

#316

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA (2003) (1115)
The Challenge of Finding a Cure for HIV Infection (2009) (879)
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. (1998) (461)
Pathogenesis of infection with human immunodeficiency virus. (1987) (445)
Cellular reservoirs of HIV‐1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry (1996) (442)
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. (1999) (416)
Inflammatory Reactions in HIV-1Infected Persons after Initiation of Highly Active Antiretroviral Therapy (2000) (409)
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency (1990) (358)
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. (2001) (323)
Antiviral potentials of medicinal plants (2007) (304)
Twenty years of therapy for HIV-1 infection (2003) (298)
Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. (1992) (291)
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. (2005) (275)
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. (2016) (257)
Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression (1990) (221)
Human Immunodeficiency Virus Type 1 Vpr Induces Apoptosis in Human Neuronal Cells (2000) (209)
Infection of the retina by human immunodeficiency virus type I. (1987) (193)
Detection of HIV‐1 proviral DNA in sperm from HIV‐1-infected men (1994) (172)
Human immunodeficiency virus (HIV) infection of the uterine cervix. (1988) (169)
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells (1996) (167)
A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. (2004) (150)
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. (2002) (139)
Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency (1992) (138)
Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. (1994) (136)
Hide-and-seek: the challenge of viral persistence in HIV-1 infection. (2008) (132)
Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* (2001) (129)
Human Immunodeficiency Virus Type 1 Vif Protein Is an Integral Component of an mRNP Complex of Viral RNA and Could Be Involved in the Viral RNA Folding and Packaging Process (2000) (125)
Recombinant rabies virus as potential live-viral vaccines for HIV-1. (2000) (114)
Central nervous system infections in individuals with HIV-1 infection (2002) (110)
Current status of gene therapy strategies to treat HIV/AIDS. (2005) (110)
HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy. (2004) (109)
Alcohol intake increases human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells. (1993) (107)
TAR‐independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV‐1 gene regulation. (1992) (106)
Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. (1993) (102)
Kynurenine pathway metabolism in human blood–brain–barrier cells: implications for immune tolerance & neurotoxicity (2008) (100)
Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. (2002) (99)
Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase (1996) (99)
Human Immunodeficiency Virus Type 1 Enters Primary Human Brain Microvascular Endothelial Cells by a Mechanism Involving Cell Surface Proteoglycans Independent of Lipid Rafts (2003) (98)
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. (2001) (98)
Dual infection of retina with human immunodeficiency virus type 1 and cytomegalovirus. (1989) (97)
Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. (1992) (97)
Slower Progression of HIV-1 Infection in Persons with GB Virus C Co-Infection Correlates with an Intact T-Helper 1 Cytokine Profile (2003) (95)
Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic (2003) (95)
Potent Suppression of Viral Infectivity by the Peptides That Inhibit Multimerization of Human Immunodeficiency Virus Type 1 (HIV-1) Vif Proteins* (2003) (91)
The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication (1994) (89)
The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. (2005) (83)
Reservoirs, Sanctuaries, and Residual Disease: The Hiding Spots of HIV-1 (2003) (82)
Polymerase chain reaction in situ: intracellular amplification and detection of HIV-1 proviral DNA and other specific genes. (1993) (80)
Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. (2003) (79)
Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. (1996) (79)
Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. (1996) (77)
Antimicrobial Therapy and Vaccines (1999) (77)
Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. (1993) (74)
HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission. (1999) (72)
Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. (2002) (72)
RNA interference: on the road to an alternate therapeutic strategy! (2003) (71)
Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. (2003) (69)
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial (2020) (69)
Human Immunodeficiency Virus Type 1 Nef Potently Induces Apoptosis in Primary Human Brain Microvascular Endothelial Cells via the Activation of Caspases (2005) (68)
HIV-1 latency due to the site of proviral integration. (1993) (66)
Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections (2002) (65)
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. (2002) (65)
Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. (2005) (65)
Infection of oral mucosal cells by human immunodeficiency virus type 1 in seropositive persons. (1995) (64)
Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates (2001) (64)
CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. (1992) (64)
In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months (2003) (63)
Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. (2001) (62)
Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector (2001) (62)
Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ. (2003) (60)
Primary HIV-1 resistance: a new phase in the epidemic? (1999) (60)
The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. (2003) (58)
Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cells. (2002) (57)
Diversity of HIV-1 Vpr Interactions Involves Usage of the WXXF Motif of Host Cell Proteins* (1998) (57)
Human immunodeficiency virus type I provirus is demonstrated in peripheral blood monocytes in vivo: a study utilizing an in situ polymerase chain reaction. (1993) (56)
Partial Rescue of the Vif-Negative Phenotype of Mutant Human Immunodeficiency Virus Type 1 Strains from Nonpermissive Cells by Intravirion Reverse Transcription (2000) (55)
Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. (2004) (54)
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals (1994) (54)
Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo (1996) (54)
Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. (2000) (52)
Antiviral Effects of Human Immunodeficiency Virus Type 1-Specific Small Interfering RNAs against Targets Conserved in Select Neurotropic Viral Strains (2004) (52)
IL-7 as a potential therapy for HIV-1-infected individuals (2005) (52)
Reduction of Serum Melatonin Levels in HIV-1-Infected Individuals’ Parallel Disease Progression: Correlation with Serum Interleukin-12 Levels (2003) (50)
Identification of an RNA element that confers post-transcriptional repression of connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) gene: Similarities to retroviral RNA-protein interactions (2000) (49)
Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. (2001) (48)
TAR-independent replication of human immunodeficiency virus type 1 in glial cells (1992) (48)
Residual HIV-1 disease in the era of highly active antiretroviral therapy. (1999) (47)
Genetic therapies for HIV infections: promise for the future. (1995) (47)
Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. (2003) (46)
Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. (1996) (45)
Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat (1994) (45)
Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition (1996) (43)
Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. (2003) (42)
Nuclear and nucleolar targeting of human ribosomal protein S25: Common features shared with HIV-1 regulatory proteins (1999) (42)
HIV type 1 cervicovaginal reservoirs in the era of HAART. (2005) (42)
Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. (2002) (41)
RNA interference meets HIV-1: Will silence be golden? (2002) (41)
AIDS Dementia and HIV-1-Induced Neurotoxicity: Possible Pathogenic Associations and Mechanisms. (1996) (40)
Rev Binds Specifically to a Purine Loop in the SL1 Region of the HIV-1 Leader RNA* (2003) (40)
Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. (1994) (39)
Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase by Intracellular Expression of Single-Chain Variable Fragments To Inhibit Early Stages of the Viral Life Cycle (2001) (38)
Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein (1996) (38)
Caffeine Inhibits Human Immunodeficiency Virus Type 1 Transduction of Nondividing Cells (2005) (37)
High percentages of CD4‐positive lymphocytes harbor the HIV‐1 provirus in the blood of certain infected individuals (1993) (37)
Sodium butyrate stimulation of HIV-1 gene expression: a novel mechanism of induction independent of NF-kappa B. (1995) (37)
The long terminal repeat is not a major determinant of the cellular tropism of human immunodeficiency virus type 1 (1991) (37)
Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways. (2005) (36)
HIV and GB virus C--can two viruses be better than one? (2004) (36)
Pathogenesis of HIV-1 Infection Within Bone Marrow Cells (2000) (36)
Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection (2005) (36)
Human studies on alcohol and susceptibility to HIV infection. (1994) (35)
Rabies virus glycoprotein as a carrier for anthrax protective antigen (2006) (35)
Lentiviral expression of HIV-1 Vpr induces apoptosis in human neurons (2011) (34)
Rhabdovirus-Based Vectors with Human Immunodeficiency Virus Type 1 (HIV-1) Envelopes Display HIV-1-Like Tropism and Target Human Dendritic Cells (2002) (34)
Seminal reservoirs during an HIV type 1 eradication trial. (2005) (34)
Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells (2000) (34)
Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. (2000) (32)
Black Death: AIDS in Africa (2003) (32)
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis (2020) (32)
The human immunodeficiency virus type 1 Rev protein: a pivotal protein in the viral life cycle. (1995) (31)
Nucleo-cytoplasmic redistribution of the HTLV-I Rex protein: alterations by coexpression of the HTLV-I p21x protein. (1996) (31)
The HIV‐1 Vpr co‐activator induces a conformational change in TFIIB (1999) (31)
siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. (2006) (30)
Increasing transduction efficiency of recombinant murine retrovirus vectors by initiation of endogenous reverse transcription: potential utility for genetic therapies (1995) (30)
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. (2007) (30)
Anti-human immunodeficiency virus type 1 activity of sulfated monosaccharides: comparison with sulfated polysaccharides and other polyions. (1991) (29)
Glucocorticoid-mediated inhibition of interleukin-2 receptor α and -β subunit expression by human T cells (1994) (28)
Cellular latency of human immunodeficiency virus type 1. (1992) (28)
Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells. (1994) (28)
Effects of HIV-1 Vpr on neuroinvasion and neuropathogenesis. (2004) (27)
The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity. (2004) (27)
Combination genetic therapy to inhibit HIV-1. (2002) (27)
Initiating antiretroviral therapy during HIV infection: confusion and clarity. (2001) (27)
Natural endogenous reverse transcription of HIV-1. (1998) (27)
Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. (2003) (26)
Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell. (1996) (25)
HIV-1 Vpr potently induces programmed cell death in the CNS in vivo. (2007) (24)
Molecular Interactions of Human Immunodeficiency Virus Type 1 with Primary Human Oral Keratinocytes (2005) (24)
Pentoxifylline Suppresses Transduction by HIV-1-Based Vectors (2007) (24)
A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat. (1995) (24)
Attenuation of HIV-1 infection by other microbial agents. (2005) (22)
Intracellular Expression of Single-Chain Variable Fragments To Inhibit Early Stages of the Viral Life Cycle by Targeting Human Immunodeficiency Virus Type 1 Integrase (1998) (22)
Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. (2002) (22)
Absence of the inducible form of nitric oxide synthase in the brains of patients with the acquired immunodeficiency syndrome. (1997) (21)
A cis-acting peptide signal in human immunodeficiency virus type I Rev which inhibits nuclear entry of small proteins (1998) (21)
Evidence that a cell cycle regulator, E2F1, down-regulates transcriptional activity of the human immunodeficiency virus type 1 promoter (1995) (21)
The role of CD8-positive lymphocytes in the control of HIV-1 infection of peripheral blood mononuclear cells. (1993) (21)
HIV-1 gene therapy: promise for the future. (2000) (21)
Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes (2003) (20)
Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging. (2006) (20)
Applications of In Situ PCR Methods in Molecular Biology (1995) (20)
Immunogenicity Study of Glycoprotein-Deficient Rabies Virus Expressing Simian/Human Immunodeficiency Virus SHIV89.6P Envelope in a Rhesus Macaque (2004) (20)
Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. (2003) (19)
A quantitative reverse transcriptase-polymerase chain reaction for HIV-1-specific RNA species. (1992) (19)
Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase by Intracellular Expression of Single-Chain Variable Fragments To Inhibit Early Stages of the Viral Life Cycle (1998) (19)
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. (2002) (19)
Potent Inhibition of Human Immunodeficiency Virus Type 1 in Primary T Cells and Alveolar Macrophages by a Combination Anti-Rev Strategy Delivered in an Adeno-Associated Virus Vector (1998) (19)
Cis/trans-activation of the interleukin-9 receptor gene in an HTLV-I-transformed human lymphocytic cell. (1996) (18)
Inhibition of HIV-1 in the central nervous system by IFN-alpha2 delivered by an SV40 vector. (2003) (18)
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis (2009) (17)
Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248) (2004) (15)
Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. (2000) (14)
Natural endogenous reverse transcription of HIV type 1. (1998) (14)
Glucocorticoid-mediated inhibition of interleukin-2 receptor alpha and -beta subunit expression by human T cells. (1994) (14)
Cholesterol-Depleting Statin Drugs Protect Postmitotically Differentiated Human Neurons against Ethanol- and Human Immunodeficiency Virus Type 1-Induced Oxidative Stress In Vitro (2006) (13)
ATM: HIV-1's Achilles heel? (2005) (13)
Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons. (2005) (13)
Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo. (2003) (13)
HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host. (2004) (12)
HIV: A tough viral nut to crack (2002) (12)
Replication of lentiviruses. (2003) (12)
Natural endogenous reverse transcription of simian immunodeficiency virus. (1997) (12)
Eliminating HIV-1 reservoirs. (2002) (12)
Chemokine receptors and the molecular basis for human immunodeficiency virus type 1 entry into peripheral hematopoietic stem cells and their progeny. (1998) (12)
Frequency of cells positive for HIV‐1 sequences assessed by in situ polymerase chain reaction (1993) (11)
Association of Provider and Patient Characteristics With HIV‐Infected Women's Antiretroviral Therapy Regimen (2001) (11)
The nuclear function of the nuclear diffusion inhibitory signal of human immunodeficiency virus type 1: critical roles in dominant nuclear localization and intracellular stability. (2000) (11)
HIV: Cross-talk and viral reservoirs (2003) (11)
Cross-Packaging of Human Immunodeficiency Virus Type 1 Vector RNA by Spleen Necrosis Virus Proteins: Construction of a New Generation of Spleen Necrosis Virus-Derived Retroviral Vectors (2004) (11)
Antiretroviral therapy in the developing world. (2005) (10)
Residual HIV-1 persistence during suppressive HAART. (2001) (10)
New methods for the detection of HIV. (2002) (10)
Immune Reconstitution Syndrome in AIDS (2003) (10)
In situ Polymerase Chain Reaction and Hybridization to Detect Low‐Abundance Nucleic Acid Targets (1996) (9)
Effects of highly active antiretroviral therapy on HIV-1-associated oral complications. (2007) (9)
HIV-1 reservoirs. (2002) (9)
In situ polymerase chain reaction and HIV-1. (1994) (9)
Anti-HIV-1 microbicides -- 'chemical condoms' designed to limit the scourge of the HIV-1 pandemic. (2005) (9)
Binding of Intracellular Anti-Rev Single Chain Variable Fragments to Different Epitopes of Human Immunodeficiency Virus Type 1 Rev: Variations in Viral Inhibition (1998) (8)
Modulation of HTLV-I gene expression by HIV-1 Rev through an alternative RxRE-independent pathway mediated by the RU5 portion of the 5'-LTR. (1998) (8)
Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. (1998) (8)
A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide. (1999) (8)
Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. (2001) (8)
RNA interference:a potential novel therapeutic combating HIV-1 in the central nervous system. (2004) (7)
A trans-dominant negative HIV type 1 Rev with intact domains of NLS/NOS and NES. (2002) (6)
Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides. (2006) (5)
T-cells and excitotoxicity (2007) (5)
Gene Therapy and HIV-1 Infection (2002) (5)
Interferon and human immunodeficiency virus infection. (1987) (5)
Unsung Hero Robert C. Gallo (2009) (4)
Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection. (2005) (4)
The HIV-1 Vif protein: a paradigm for viral:cell interactions (2003) (4)
Cellular latency in HIV-1 infection. (1994) (4)
How HIV resists eradication. (1998) (4)
85 - SER-287, an Investigational Microbiome Therapeutic, Induces Remission and Endoscopic Improvement in a Placebo-Controlled, Double-Blind Randomized Trial in Patients with Active Mild-to-Moderate Ulcerative Colitis (2018) (4)
Novel Inhibitory Effects of γ-Glutamylcysteine Ethyl Ester against Human Immunodeficiency Virus Type 1 Production and Propagation (1998) (4)
Hepatitis A vaccines: past, present, and future. (1993) (4)
Residual HIV-1 replication. (2000) (4)
Hepatitis B and human immunodeficiency virus: double trouble. (1991) (3)
Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication. (2004) (3)
HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif. (1999) (3)
Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector design. (2004) (3)
Detection of HIV-1 Gene Sequences in Brain Tissues by in Situ Polymerase Chain Reaction (1995) (2)
Therapy of human immunodeficiency virus infections. (1987) (2)
Erratum: Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: Variations in viral inhibition (Journal of Virology (1996) 70:5 (3290-3297)) (1998) (2)
HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy. (1999) (2)
DNA and amino acid sequence of anti-HIV-1 Rev sFv. (1997) (2)
[23] Detection of HIV-1 in brain tissue of individuals with AIDS by in situ gene amplification (1995) (1)
Gene Therapy for HIV-1 Infection (2002) (1)
HIV-1 and Other Neurodegenerative Disorders (2005) (1)
Book Review Management of the HIV-Infected Patient Second edition. Edited by Suzanne Crowe, Jennifer Hoy, and John Mills. 630 pp., illustrated. London, Martin Dunitz, 2002. $190. 1-901865-28-2 (2002) (1)
HIV-1 Reservoirs and Residual Viral Replication during Highly Active Antiretroviral Therapy (2005) (1)
Infectious DiseaseInfectious Disease (2003) (1)
Reply to Lagier et al. (2017) (0)
First International Workshop on HIV-1 Persistence During Therapy. (2004) (0)
Clinical Virology: Clinical Virology (2003) (0)
Reverse Transcription from Nonpermissive Cells by Intravirion Immunodeficiency Virus Type 1 Strains Phenotype of Mutant Human Partial Rescue of the Vif-Negative (2000) (0)
999. siRNA-Mediated Interference of Double-Stranded RNA Binding Protein [E3L] Is an Effective Strategy to Inhibit Vaccinia Virus (2005) (0)
HUMAN HERPESVIRUS 8 DNA SEQUENCES IN CD8+ T CELLS. AUTHORS' REPLY (1997) (0)
AIDS 2001. Virology. Overview. (2001) (0)
Immune reconstitution syndrome in AIDS. Interview by Vicki Glaser. (2003) (0)
transactivation by Tat. vitro and facilitates TAR-independent immunodeficiency virus type 1 transcription in kappa B-binding activity that enhances human Central nervous system-derived cells express a (2013) (0)
with Human Immunodeficiency Virus Type 1 Blocked Early-Stage Latency in the Peripheral Blood Cells of Certain Individuals Infected (2006) (0)
In situ detection of HIV-1 and HPV in normal and dysplastic cervical tissue by PCR (1999) (0)
Intracellular Expression of Single-Chain Variable Fragments To Inhibit Early Stages of the Viral Life Cycle by Targeting Human Immunodeficiency Virus Type 1 Integrase (2001) (0)
Erratum: Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector (Journal of Virology 71:5 (4071-4078)) (1998) (0)
Initiating Antiretroviral Therapy During HIV Infection (2017) (0)
Presence of HHV-8 in the Sperm of HIV-1 Infected Individuals: 27 (1997) (0)
Erratum: Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein (Journal of Virology 70:2 (1282- 1287)) (1998) (0)
Proceedings of the National Academy of Sciences (1998) (0)
Clinical HIV-1 virology. (2002) (0)
Generation of retroviral particles for the spleen necrosis virus (SNV)-based vector system and their use in transduction of various cell types. (2010) (0)
Role of Lentiviral Lytic Polypeptide I (LLP-I) in the Selective Cytotoxicity of γ-Glutamylcysteine Ethyl Ester against Human Immunodeficiency Virus Type 1-Producing Cells (1999) (0)
225 New Viral and Tuberculosis Therapeutics for the 21st Century (2009) (0)
Method of preventing or treating infection by HIV. (1999) (0)
Human herpesvirus 8 DNA sequences in CD8+ T cells [1] (multiple letters) (1997) (0)
HIV-1 infection and genomics: sorting out the complexity. (2004) (0)
Prevention and treatment of immunodeficiency virus infection caused by a (1999) (0)
AIDS 2002. Virology: overview. (2002) (0)
Clinical Infectious Disease: Antiviral Therapy (2008) (0)
Molecular Diagnostic Techniques and Other Tests for Direct Detection of HIV (2003) (0)
Drug Sanctuaries, Low Steady State Viral Loads and Viral Blips. (2002) (0)
Binding of Intracellular Anti-Rev Single Chain Variable Fragments to Different Epitopes of Human Immunodeficiency Virus Type 1 Rev: Variations in Viral Inhibition (2001) (0)
Nuclear Preservation and Cytoplasmic Degradation of Human Immunodeficiency Virus Type 1 Rev Protein (1998) (0)
Neurovirological Aspects of HIV Infection in the HAART Era (2009) (0)
Single Chain Variable Fragment Based Strategies for Anti-HIV-1 Gene Therapy: Targeting the Viral Preintegration Complex and Combination MolecUlar Approaches (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz?

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz is affiliated with the following schools:

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz's Academic­Influence.com Rankings

Why Is Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz Influential?

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz's Published Works

Published Works

What Schools Are Affiliated With Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz?

Roger J. Th. Jef. Uni. Div. Infec. Dis. Pomerantz's AcademicInfluence.com Rankings